Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 96 | UKINETS2023 | Next issue

UKI NETS 21st National Conference

ea0096oc1 | Section | UKINETS2023

Novel phenotypic and exonic variants for Neuroendocrine Neoplams: a UK Biobank study

Green Dr. Harry , Rous Dr. Brian , Hawkes Dr. Gareth , Trinidad Moreno-Montilla Maria , Nwoguh Chinonso , John Ramage Prof , Thirlwell Prof Chrissie

Neuroendocrine neoplasms (NENs) are a heterogeneous tumour classification including indolent neuroendocrine tumours (NETs), aggressive neuroendocrine carcinomas (NECs). NECs and small cell lung cancer (SCLCs) are poorly differentiated tumours and life expectancy following metastatic diagnosis is less than 1 year. Currently, there are known variants in germline DNA that associate with bronchial and pancreatic NENs, but not intestinal. We conducted an exome-wide association stud...

ea0096oc2 | Section | UKINETS2023

Interim analysis of Lantana: A phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours (NCT05178693)

Rzeniewicz Karolina , Ward Caroline , Khan Sairah , Naik Mitesh , Barwick Tara , Aboayge Eric , Sharma Rohini

Background: Peptide-receptor-radionuclide-therapy (PRRT) improves progression free survival in metastatic neuroendocrine neoplasia (NEN). To be suitable for PRRT, somatostatin receptor-2 (SSTR2) must be present on tumour site as determined by positive uptake on [68Ga]Ga-DOTA-peptide-PET/CT. LANTana is an ongoing study evaluating whether treatment with the demethylating agent, ASTX727, results in re-expression of SSTR2, as determined by [68Ga]Ga-DOTA-peptide-PE...

ea0096oc3 | Section | UKINETS2023

Factors affecting overall survival after surgery for lung neuroendocrine tumours: A single centre series

Mortagy Dr. Mohamed , Nonaka Dr. Daisuke , Dolly Dr. Saoirse , Srirajaskanthan Dr. Raj , Clement Dr. Dominique , Bille Mr. Andrea , Juliet King Miss , Ramage Dr. John

Introduction: Surgery is the only known curative therapy for lung/bronchial neuroendocrine tumours (NET). Factors that affect survival after surgery for lung NET are not clear, and hence follow up protocols are not evidence-based.Methods: We collected data on 318 prospective patients that were operated on at a single centre between 2012 and 2020 (Guys and St Thomas’s regional thoracic surgery unit). The aim was to g...